Randomized trial of sertraline versus venlafaxine XR in major depression: Efficacy and discontinuation symptoms

Basit Öğe Kaydı
dc.contributor.authorSir, A
dc.contributor.authorD'Souza, RF
dc.contributor.authorUguz, S
dc.contributor.authorGeorge, T
dc.contributor.authorVahip, S
dc.contributor.authorHopwood, M
dc.contributor.authorMartin, AJ
dc.date.accessioned2024-04-24T17:24:12Z
dc.date.available2024-04-24T17:24:12Z
dc.date.issued2005
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The comparative efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepmephrine reuptake inhibitors (SNRIs) was recently debated. Meta-analyses, based mainly on fluoxetine comparator data, suggest that the SNRI venlafaxine has superior efficacy to SSRIs in treatment of major depression. Objective: To compare quality of life (QOL), efficacy, safety, and tolerability associated with sertraline and venlafaxine extended release (XR) for treatment of DSM-IV major depression. Method: This was an 8-week, double-blind, randomized study of sertraline (50-150 mg/day) versus venlafaxine XR (75-225 mg/day), followed by a 2-week taper period. Subjects were recruited from 7 sites in Turkey and 6 sites in Australia between October 2002 and July 2003. The primary outcome measure was the Quality of Life Enjoyment and Satisfaction Questionnaire. Secondary outcome measures included measures of depression (including response and remission), anxiety, pain, safety (e.g., blood pressure), and tolerability (e.g., discontinuation symptoms). Results: A total of 163 subjects received study treatment (women, 69%; mean age, 37.0 [SD = 12.9] years). No significant differences in QOL or efficacy were noted between treatments on the primary or secondary endpoints for the total study population or the anxious depression and severe depression subgroups. A priori analyses of symptoms associated with treatment discontinuation demonstrated no difference between treatment groups. However, in post hoc analyses, sertraline was associated with less burden of moderate to severe discontinuation symptoms. Venlafaxine XR was associated with a relative increase in mean blood pressure (supine diastolic blood pressure, -4.4 mm Hg difference at week 8/last observation carried forward). Conclusion: Sertraline and venlataxine XR demonstrated comparable effects on QOL and efficacy in treatment of major depression, although sertraline may be associated with a lower symptom burden during treatment discontinuation and a reduced risk of blood pressure increase.en_US
dc.identifier.doi10.4088/JCP.v66n1015
dc.identifier.endpage1320en_US
dc.identifier.issn0160-6689
dc.identifier.issue10en_US
dc.identifier.pmid16259546
dc.identifier.scopus2-s2.0-27544459825
dc.identifier.scopusqualityQ1
dc.identifier.startpage1312en_US
dc.identifier.urihttps://doi.org/10.4088/JCP.v66n1015
dc.identifier.urihttps://hdl.handle.net/11468/19510
dc.identifier.volume66en_US
dc.identifier.wosWOS:000232911500015
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPhysicians Postgraduate Pressen_US
dc.relation.ispartofJournal of Clinical Psychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleRandomized trial of sertraline versus venlafaxine XR in major depression: Efficacy and discontinuation symptomsen_US
dc.titleRandomized trial of sertraline versus venlafaxine XR in major depression: Efficacy and discontinuation symptoms
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu